Malignant astrocytic gliomas in children.
Between 1957 and 1980, 54 children less than 20 years of age with a diagnosis of glioblastoma multiforme or malignant astrocytoma were treated. All patients had a minimum follow-up period of 5 years. Twenty-seven patients had glioblastoma multiforme and 27 had malignant astrocytoma. The median age was 8 years for glioblastoma multiforme patients and 10 years for malignant astrocytoma patients. All patients received radiation therapy, but two died of postoperative complications and did not complete the treatment. The Kernohan Grading System was more useful in distinguishing glioblastoma multiforme and malignant astrocytoma in terms of prognosis than was the Nelson criterion of tumor necrosis. Glioblastoma multiforme (IV) patients had survivals of 44% at 1 year, 26% at 2 years, 4% at 5 years, and 0% at 10 years. Malignant astrocytoma (III) patients had 74% survival at 1 year, 56% at 2 years, 36% at 5 years, and 32% at 10 years, (all P less than 0.05). The tumor dose and tumor location affected survival significantly. Patients with hemispheric malignant astrocytoma who received 54-60 Gy had a 60% 5-year survival rate compared to 14% for doses of 35-50 Gy. Glioblastoma multiforme patients with noncentral tumors had a 9% 5- year survival with 54-60 Gy versus 0% with 35-50 Gy. Cerebral and cerebellar hemispheric tumors did better than central tumors. There were no 5-year survivors among patients with central tumors. Noncentral tumors, on the other hand, resulted in a 44% 5-year survival for malignant astrocytoma and 5% for glioblastoma multiforme. Radiation therapy was well tolerated during the acute period. Only one patient developed a late neurologic deficit attributable to therapy. The patient had hearing loss after two courses of 50 Gy each to a temporal lobe tumor. However, six of the 11 patients who survived for 5 years or longer had intellectual, emotional, or endocrine dysfunction.
Marchese
M J
MJ
Department of Radiation Oncology, Columbia-Presbyterian Medical Center, New York, New York.
Chang
C H
CH
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001254:Astrocytoma / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D001932:Brain Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D002648:Child; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D005909:Glioblastoma / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D005910:Glioma / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local; D009460:Neurologic Examination; D011379:Prognosis; D011879:Radiotherapy Dosage; D012074:Remission Induction; D012189:Retrospective Studies; D015996:Survival Rate